No Dice

The Wall Street Journal's Deal Book wonders why there are so few deals going on in Europe's biopharma arena -- $137 billion of health-care deals have gone down so far this year in the US. It's not for lack of trying. "One potential deal after another has fallen apart," the article says, citing companies such as Nycomed, Crucell, and Actavis that have explored sales only to have them fall through.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.